vs
Side-by-side financial comparison of Mayville Engineering Company, Inc. (MEC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $134.3M, roughly 1.3× Mayville Engineering Company, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -3.2%, a 4.9% gap on every dollar of revenue. On growth, Mayville Engineering Company, Inc. posted the faster year-over-year revenue change (10.7% vs 5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -8.8%).
Mayville Engineering Company, Inc. is a U.S.-headquartered leading manufacturer of metal components, fabricated assemblies, and custom engineered solutions. It serves OEM clients across agriculture, construction, transportation, defense, and power sports markets, offering end-to-end services from prototyping to high-volume production for North America.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
MEC vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $134.3M | $177.4M |
| Net Profit | $-4.4M | $2.9M |
| Gross Margin | 6.8% | — |
| Operating Margin | -4.1% | 3.9% |
| Net Margin | -3.2% | 1.6% |
| Revenue YoY | 10.7% | 5.0% |
| Net Profit YoY | -127.3% | — |
| EPS (diluted) | $-0.22 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $134.3M | $196.9M | ||
| Q3 25 | $144.3M | $179.5M | ||
| Q2 25 | $132.3M | $181.1M | ||
| Q1 25 | $135.6M | $168.9M | ||
| Q4 24 | $121.3M | $187.3M | ||
| Q3 24 | $135.4M | $168.6M | ||
| Q2 24 | $163.6M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-4.4M | — | ||
| Q3 25 | $-2.7M | $5.4M | ||
| Q2 25 | $-1.1M | $-4.8M | ||
| Q1 25 | $20.0K | $4.8M | ||
| Q4 24 | $16.0M | — | ||
| Q3 24 | $3.0M | $-143.5M | ||
| Q2 24 | $3.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 79.5% | ||
| Q3 25 | 11.0% | 80.9% | ||
| Q2 25 | 10.3% | 77.4% | ||
| Q1 25 | 11.3% | 79.7% | ||
| Q4 24 | 8.9% | 78.7% | ||
| Q3 24 | 12.6% | 76.9% | ||
| Q2 24 | 13.6% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -4.1% | 1.2% | ||
| Q3 25 | 0.0% | 3.5% | ||
| Q2 25 | 0.1% | 4.7% | ||
| Q1 25 | 1.2% | 1.2% | ||
| Q4 24 | 19.0% | 13.2% | ||
| Q3 24 | 4.2% | -82.8% | ||
| Q2 24 | 5.0% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -3.2% | — | ||
| Q3 25 | -1.9% | 3.0% | ||
| Q2 25 | -0.8% | -2.7% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 2.2% | -85.1% | ||
| Q2 24 | 2.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.22 | $0.05 | ||
| Q3 25 | $-0.13 | $0.12 | ||
| Q2 25 | $-0.05 | $-0.11 | ||
| Q1 25 | $0.00 | $0.10 | ||
| Q4 24 | $0.76 | $0.38 | ||
| Q3 24 | $0.14 | $-3.11 | ||
| Q2 24 | $0.18 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $240.7M | $653.9M |
| Total Assets | $563.6M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $1.5M | $238.4M | ||
| Q3 25 | $1.2M | $246.3M | ||
| Q2 25 | $206.0K | $445.9M | ||
| Q1 25 | $183.0K | $493.6M | ||
| Q4 24 | $206.0K | $484.6M | ||
| Q3 24 | $178.0K | $453.8M | ||
| Q2 24 | $314.0K | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $240.7M | $693.1M | ||
| Q3 25 | $244.8M | $727.2M | ||
| Q2 25 | $246.8M | $757.8M | ||
| Q1 25 | $250.0M | $798.5M | ||
| Q4 24 | $251.8M | $778.3M | ||
| Q3 24 | $238.4M | $749.6M | ||
| Q2 24 | $238.1M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $563.6M | $1.3B | ||
| Q3 25 | $585.6M | $1.3B | ||
| Q2 25 | $433.7M | $1.5B | ||
| Q1 25 | $447.7M | $1.6B | ||
| Q4 24 | $445.6M | $1.6B | ||
| Q3 24 | $466.0M | $1.5B | ||
| Q2 24 | $488.2M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.4M | — |
| Free Cash FlowOCF − Capex | $10.2M | — |
| FCF MarginFCF / Revenue | 7.6% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $26.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $13.4M | $43.7M | ||
| Q3 25 | $1.9M | $60.8M | ||
| Q2 25 | $15.0M | $12.0M | ||
| Q1 25 | $8.3M | $35.5M | ||
| Q4 24 | $38.0M | $33.1M | ||
| Q3 24 | $17.9M | $53.9M | ||
| Q2 24 | $23.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $10.2M | $43.5M | ||
| Q3 25 | $-1.1M | $57.0M | ||
| Q2 25 | $12.5M | $9.3M | ||
| Q1 25 | $5.4M | $26.9M | ||
| Q4 24 | $35.6M | $31.0M | ||
| Q3 24 | $15.1M | $49.8M | ||
| Q2 24 | $19.2M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 22.1% | ||
| Q3 25 | -0.8% | 31.7% | ||
| Q2 25 | 9.5% | 5.1% | ||
| Q1 25 | 4.0% | 15.9% | ||
| Q4 24 | 29.4% | 16.6% | ||
| Q3 24 | 11.1% | 29.6% | ||
| Q2 24 | 11.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 0.1% | ||
| Q3 25 | 2.1% | 2.2% | ||
| Q2 25 | 1.8% | 1.5% | ||
| Q1 25 | 2.2% | 5.1% | ||
| Q4 24 | 1.9% | 1.1% | ||
| Q3 24 | 2.1% | 2.4% | ||
| Q2 24 | 2.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | 416.65× | 7.37× | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 6.03× | — | ||
| Q2 24 | 6.15× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEC
| Fabrication | $72.2M | 54% |
| Construction And Access | $19.2M | 14% |
| Tubes | $16.2M | 12% |
| Other Market | $11.9M | 9% |
| Agriculture | $7.7M | 6% |
| Military | $6.7M | 5% |
| Outdoor Sports | $1.7M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
